Asset
NERATINIB
Puma Biotechnology Inc Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00398567 | phase1_2 | completed | 2007-04-04 | 2009-07-31 | Puma Biotechnology, Inc. | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer |
| NCT00445458 | phase1_2 | completed | 2007-09-11 | 2011-05-01 | Puma Biotechnology, Inc. | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
| NCT00266877 | phase2 | completed | 2005-12-01 | 2009-01-01 | Puma Biotechnology, Inc. | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.